AGIO:NASDAQ
Agios Pharmaceuticals Inc
35,10 $
arrow_upward
+2,75%(+0,94) 1D
35,10 $
0,00% (0,00)
bedtimeAfter hours
Closed: 22 հնս, 16:00:01 GMT-4 · USD
search
All symbols
1D
5D
1M
6M
YTD
1Y
5Y
MAX
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for AGIO...
Open
34,30 $
High
35,53 $
Low
34,30 $
Mkt. cap
2,09 մլրդ
Avg. vol.
941,55 հզր
Volume
1,38 մլն
52-wk high
45,99 $
52-wk low
22,24 $
EPS
-7,25 $
Beta
0,59
Shares outstanding
59,47 մլն
No. of employees
540
Open
34,30 $
High
35,53 $
Low
34,30 $
Mkt. cap
2,09 մլրդ
Avg. vol.
941,55 հզր
Volume
1,38 մլն
52-wk high
45,99 $
52-wk low
22,24 $
EPS
-7,25 $
Beta
0,59
Shares outstanding
59,47 մլն
No. of employees
540
News stories
From sources across the web
Honolulu Star-Advertiser
·
17 րոպե առաջ
S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech
TechStock²
·
44 րոպե առաջ
Marvell Added to S&P 500 but Shares Fall
Profile
Agios Pharmaceuticals Inc. is a publicly trading American pharmaceutical company pioneering therapies for genetically defined diseases, with a near-term focus on developing therapies for hemolytic anemias. The company was founded in 2008 by Lewis Cantley, Tak Mak and Craig Thompson. Agios is a Delaware corporation headquartered in Cambridge, Massachusetts. The company tendered an initial public offering in July 2013. Wikipedia
About Agios Pharmaceuticals Inc
AI content may include mistakes. Learn more